News
-
-
PRESS RELEASE
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Study shows tolebrutinib delays disability progression in non-relapsing secondary progressive MS by 31%; global regulatory submissions in H2 2024. ECTRIMS 2024 data presented -
-
-
-
-
-
PRESS RELEASE
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
Dupixent achieves significant improvements in disease remission and symptoms in bullous pemphigoid study. Study met primary and key secondary endpoints with beneficial steroid-sparing effect -
-
